Company intelligence / Profile preview

ECAPFIN

Mexico City, Mexico City, Mexico

Ownership: Private
Development stage: Other

Overview

ECAPFIN was a Mexico City-based private company focused on green biotechnology and environmental services rather than human therapeutics or healthcare. Public deal disclosures indicate the company developed biotech and technical know-how related to cultivation and use of nopal cactus for biological carbon sequestration, carbon-credit generation, and commercialization of related food and renewable bio-energy products. The company does not appear to have a conventional drug-development pipeline, therapeutic targets, or clinical-stage assets. ECAPFIN was acquired by Itoco in March 2021 through an asset acquisition transaction.

Industry: Non-Drug Biotech

Partnerships

Itoco asset acquisition transaction

Beyond the preview

Go deeper on ECAPFIN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECAPFIN.

Explore the full profile